Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform
Eli Lilly's obesity lead is only the starting point. See what its pipeline, manufacturing build-out, pricing pressure, and earnings trajectory could mean for the stock's next chapter.
Overview
Eli Lilly (NYSE: LLY) is trying to turn blockbuster obesity drugs into something much bigger. Its path to $1,500 depends on whether new medicines, additional indications, manufacturing scale, and rising patient volumes can generate durable earnings sufficient to overcome pricing pressure and a demanding valuation.
Stock prices used were the market prices of Sept. 15, 2026. The video was published on Oct. 7, 2026.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.